Drug Retail
-
Sign-Ups For Novo Nordisk's Weight Loss Drug Soar In US
Novo Nordisk's weight loss drug Wegovy experiences booming sign-ups in the US, while facing pricing pressures and emerging competition.
-
ALT Stock Short Report Raises Concerns over Altimmune's Weight-Loss Drug
Altimmune Inc. faces disappointment with its weight-loss drug, leading to a 19% stock drop. What does this mean for retail investors? Find out here.
-
Investors Watch as Novo Nordisk Pours Billions into Obesity Drugs
Novo Nordisk invests $2.3 billion in France to expand its weight-loss drug production, marking a significant move in the pharmaceutical industry.
-
FDA Approves Eli Lilly's Weight Loss Drug Zepbound
Eli Lilly's Tirzepatide drug, already approved for treating Type 2 diabetes as Mounjaro, has received FDA approval for weight management under the...
-
Labor Dispute Hits CVS and Walgreens
A worker walkout at CVS and Walgreens poses investment questions. Learn more about potential impacts on retail investors.
-
Safe Supply's Vision Includes Bet on Legal Cocaine
Safe Supply (SPLY) presents a visionary bet on legal cocaine. Explore retail investment potential in drug policy reform.
